Strategic funding Antiverse recently secured a $9.3M Series A led by Soulmates Ventures with participation from multiple investors, signaling strong investor confidence and potential for larger-scale collaborations or co-development deals in AI-driven antibody design.

CFTR collaboration The company is actively partnering with the Cystic Fibrosis Foundation to design novel antibodies targeting CFTR, presenting a clear entry point for partnership discussions, joint research programs, and potential grant-funded opportunities.

AI-enabled platform Leveraging AI-driven antibody design and machine learning to tackle difficult targets like GPCRs and ion channels creates a compelling value proposition for pharma and biotech buyers seeking faster, more accurate therapeutic discovery.

Geographic reach With headquarters in Cardiff and offices in Boston, Antiverse has a transatlantic footprint that aligns with early-access or regional partnerships in both the UK/EU and North America, expanding potential go-to-market routes.

Clinical-target focus Recent activity around extracellular CFTR targeting suggests capability in translational research and potential for diagnostic or therapeutic antibody programs, enabling cross-sell opportunities into cystic fibrosis and related chronic disease markets.